We are very happy to announce the launch of Version One Ventures III with $45M…
Version One
A few weeks ago I shared my reflections on my first year as a GP. Along with all the well wishes (thank you!!), many asked what Version One is investing in these days. Our portfolio companies aren’t as quick to publicize fundraising rounds like they used to and as such, we’re not making as many […]
We are very happy to announce the launch of Version One Ventures III with $45M…
We’re thrilled to announce the closing of two new funds: Fund IV ($70M USD) and…
A few weeks ago I shared my reflections on my first year as a GP. Along with all the well wishes (thank you!!), many asked what Version One is investing in these days. Our portfolio companies aren’t as quick to publicize fundraising rounds like they used to and as such, we’re not making as many public announcements about our activity.
So, as a follow up, I thought I’d share some high level stats on our investing activity since we kicked off Fund III nearly a year ago in October 2018.
These trends align with a tweet that Boris wrote last week and here are the main takeaways of our investing thesis and strategy…
We are geographically agnostic, though focused on North America with main “hubs” in SF, Toronto, NYC, and Seattle.
We invest in early stage: we now lead pre-seed rounds (typically with a $500k check) in addition to leading or participating in seed rounds (with a check of up to a $1m).
Yes, we still invest in marketplaces as this is one subset of network effects (our investment thesis).
And finally, we are not afraid in investing in hard things (i.e. robotics/hardware, healthcare/bio) or nascent markets (i.e. crypto/blockchain, AR)!
Health / Biology, Portfolio, Version One
Shifting healthcare systems from reactive to proactive care is critical – the best outcomes occur when people can take action early, before a condition becomes a diagnosis. That’s why we are excited to announce that we have led a $2.5m pre-seed round for NiaHealth and are thrilled that they are coming out of stealth and […]
We are continually refining our thesis on healthcare, from looking at clinical-grade at-home diagnostics to biotech and…
Over the past year, some of the most interesting and intellectually-stimulating pitches we heard have…